ASTELLAS PHARMA A/S: Financial statements 2023
CVR: 10888638
Source: annual report 2023, Danish Business Authority
01/04/2022 – 31/03/2023
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2023. In 2023, the company reported revenue of EUR 180,837,000 and a net result of EUR 2,081,000 compared with EUR 6,689,000 the year before. That is an increase of 0.5% compared with the year before. The profit margin was 1.2%. Equity in the 2023 report amounted to EUR 35,307,000. The solvency ratio was 31.5%. The company had 120 employees in the financial year.
- Revenue
- EUR 180,837,000
- Gross Profit
- EUR 23,101,000
- Profit/Loss
- EUR 2,081,000
- Equity
- EUR 35,307,000
- Total Assets
- EUR 112,042,000
- Employees
- 120
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 180.8M EUR | 23.1M EUR | 2.1M EUR | 35.3M EUR | 120 |
| 2022 | 179.9M EUR | 26.2M EUR | 6.7M EUR | 58.2M EUR | 120 |
| 2021 | 160.5M EUR | 24.1M EUR | 5.9M EUR | 59.4M EUR | 115 |
| 2020 | 187M EUR | 23.8M EUR | 2M EUR | 53.6M EUR | 114 |
| 2019 | 182.6M EUR | 25M EUR | 4.7M EUR | 56.2M EUR | 116 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationAbout ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.